Please assess the completion status of the following clinical trial:

Trial Title: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0-17;~* ASA Class I-II;~* Sign the informed consent form.~Exclusion Criteria:~* Patients with high risk of stomach satiety and reflux aspiration;~* Patients allergic to the study drug;~* Obesity or severe malnutrition;~* Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;~* Hypertension without treatment;~* Abnormal liver and kidney function (index ≥ 2 times the upper limit of normal reference range);~* Other congenital diseases or acute and chronic diseases that affect the observation of curative effect;~* Participate in other clinical studies within 4 weeks.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- P group (Type: ACTIVE_COMPARATOR): induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
- R group (Type: EXPERIMENTAL): induction: Remimazolam 0.3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping

Based on this trial design, predict the completion outcome and termination type (if applicable).